Pharmaceutical Intermediate Tofacitinib Citrate for Treatment Rheumatoid Arthritis

November 03, 2018

  • Model NO.: 540737-29-9
  • Customized: Non-Customized
  • Suitable for: Adult
  • Purity: >99%
  • Synonym: Xeljanz;Cp-690550;Tasocitinib Citrate
  • MW: 504.497
  • Single Impurity: ≤0.1%
  • Usage: Treat Rheumatoid Arthritis.
  • Transport Package: Discreet Package
  • Origin: China
  • Powder: Yes
  • Certification: HSE, ISO 9001
  • State: Solid
  • CAS: 540737-29-9
  • Mf: C16h20n6o.C6h8o7
  • Appearance: White Powder
  • Dosage: 30 Nm; Intraperitoneal Injection
  • Trademark: Saichuang
  • Specification: Enterprise standard
Pharmaceutical Intermediate Tofacitinib Citrate For Treatment Rheumatoid Arthritis 


Quick Detail
Product Name
Tofacitinib citrate
 
Synonym
1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE;1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate;Tofacitinib citrate (CP-690550);Tofacitinib citrate;Tasocitinib citrate;Tasocitinib citric acid s;Xeljanz;CP-690550 (Tofacitinib citrate
 
CAS
540737-29-9
 
MF
C16H20N6O.C6H8O7
 
MW
504.497
 
Appearance
White Powder
 
Assay
99%min
 
Single impurity
≤0.1%
 
Usage
Treat rheumatoid arthritis
 
Dosage
30 nM; intraperitoneal injection
 


Description

(1).Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company for treating rheumatoid arthritis, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.

(2). It can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine) . Tofacitinib citrate is approved by the daily dose of 2 times, each time 5mg. Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Tofacitinib citrate treatment showed significant improvement in clinical response and physical function.

(3). In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis. Using Tofacitinib citrate was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and
lymphoma.Tofacitinib citrate product label attaches boxed warning on these security risk.Tofacitinib citrate treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.In order to study Tofacitinib citrate long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Tofacitinib citrate therapy, and accept a integration of another group of patients approved by the treatment as a control.

Application

(1).Tofacitinib citrate is an oral, small molecule drug used to treat adults with moderate-to-severe, active rheumatoid arthritis who have not responded well to being treated with methotrexate. Methotrexate is a disease-modifying antirheumatic drug (DMARD) used to treat rheumatoid arthritis (RA).

(2).Tofacitinib acts to block the body's production of enzymes called Janus kinases (JAKs). JAKs play a role in joint inflammation in RA, which can cause pain, swelling and stiffness. If left untreated, RA inflammation could lead to joint erosions, and organ and tissue damage. It may be used alone or in combination with methotrexate or other DMARDs.

COA
ITEMS SPECIFICATION RESULTS
Appearance Off-white or white powder Conforms
Identification HPLC,NMR;LC-MS Conforms
Related substances Individual impurity≤0.5% 0.09%
Total impurities≤1.0% 0.20%
Loss on drying ≤0.5% 0.3%
Residue on ignition ≤0.1% 0.04%
Heavy metals ≤10ppm Conforms
Assay ≥98.0 % 99.1%


Use

1.Tofacitinib (INN) is a drug of the janus kinase (JAK) inhibitor class, discovered and developed by the National Institutes of Health. Tofacitinib is marketed as Xeljanz and Jakvinus.

2.It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and other countries.

3.It has demonstrated effectiveness in the treatment of psoriasis in Phase 3 studies. It is being studied for treatment of inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection.


Advantage

1,High quality with competitive price
1)Standard: Enterprise Standard
2)All Purity≥99%
3)We are manufacturer and can provide high quality products with factory price.

2,Fast and safe delivery
1)Parcel can be sent out in 24 hours after payment. Tracking number available
2)Secure and discreet shipment. Various transportation methods for your choice.
3)Customs pass rate ≥99%
4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.

3,We have clients throughout the world.
1)Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2)Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
3)High quality,competitive price,fast delivery ,first-class service gain the trust and praise from the customers.


 

Urine Bag

Disposable Urine Bag,Indwelling Catheter,Urinary Catheter

Disposable Syringes Co., Ltd. , http://www.nsmedicalcannula.com